Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

Nathan H Fowler, Loretta J Nastoupil, Frederick B Hagemeister, Sattva S Neelapu, Luis E Fayad, Denise LeBlanc, Felipe Samaniego, Chan Yoon Cheah, Nathan H Fowler, Loretta J Nastoupil, Frederick B Hagemeister, Sattva S Neelapu, Luis E Fayad, Denise LeBlanc, Felipe Samaniego, Chan Yoon Cheah

No abstract available

Keywords: lenalidomide; non-Hodgkin lymphoma; rash; rituximab.

Figures

Figure 1.

An illustrative example of a patient who developed rash during treatment with R2. Top panel, forearm. Lower panel, back.

Figure 2.

Recommended approach to rash management for lenalidomide and rituximab treatment in indolent NHL. *Supportive measures: 1. Initiate daily oral antihistamines: loratadine 10 mg/day PO or cetirizine 10 mg/day PO or diphenhydramine 25 mg/day PO. 2. Short courses of low-dose steroids: prednisone 10 mg PO ×3 days or hydrocortisone 20 mg PO once in the morning and 10 mg PO once in the evening ×3 days. 3. Continue daily oral antihistamines for the rest of the lenalidomide treatment